Skip to main content
. 2021 Feb 20;2021:1915068. doi: 10.1155/2021/1915068

Figure 1.

Figure 1

ILC subsets in the peripheral blood of HCs, patients with stable RA, and patients with active RA. (a) Gating strategy for total ILCs (CD45+CD3-Lineage-CD161+CD127+), cNK cells (CD3-CD16+/CD56+), ILC1s (CD294-CD117-), ILC2s (CD294+CD117-), and ILC3s (CD294-CD117+). (b) Absolute counts of total ILCs per mL of peripheral blood. (c) Percentage of CD16+/CD56+ cNK cells among CD3- cells. (d–f) Proportions of ILC1s, ILC2s, and ILC3s among total ILCs. (g) Correlations of the total number of ILCs with DAS28-CRP (A) and with DAS28-ESR (B). (h–j) Correlations of proportions of ILC1s, ILC2s, and ILC3s in total ILCs with DAS28-CRP (A) and DAS28-ESR (B). Data are expressed as means ± SDs and compared using the unpaired Student's t-test. Spearman's rank correlation coefficients and p values are indicated. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. RA: rheumatoid arthritis; HC: healthy control; DAS28: disease activity score for 28 joints; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. HC: n = 36; stable RA: n = 31; and active RA: n = 25.